Home > Formulary : Adult > Recent Decisions > 2013 >
Decisions 14th May 2013
Recent JFG Decisions
At the meeting on the 14th May 2013 the following decisions / changes to the formulary were agreed:
New Drug Requests
Approved
Alteplase and Dornase Alfa
- Approved clinically appropriate 26th Feb 2013. Funding arrangements now clarified awaiting NBT Directorate sign off. TLS Red
Plasmalyte® 148
- Approved for use in NBT Theatres and Critical Care NBT only. TLS red
Not approved
Aflibercept (sequential use after ranibizumab)
- Initially rejected 26th February 2013. Review of further evidence undertaken - still insufficient evidence to support sequential use
Other Decisions / Changes
-
Tolterodine first line choice for overactive bladder and remove oxybutynin
-
Pivmecillinam now for use by UHB as well as NBT
-
Cefalexin for use at NBT instead of cefradine now as oral cephalosporin. Cefradine removed from the formulary.